EVE Health Group
ASX: EVE

We Make Generic Drugs Better.

22 SEPTEMBER 2026
COFFEE MICROCAPS CONFERENCE
INVESTOR PRESENTATION
ASX: EVE

Who We Are

Dedicated to improving generic drugs for patients.

The Company

An ASX-listed Australian life sciences company building a commercial-stage pharmaceutical reformulation business. Products are supplied under SAS-B while the portfolio advances toward full product registration.

Commercial-stage. Australian. Ready to scale.

Why Reformulate?

EVE targets established medicines where formulation can reduce real patient and prescriber friction - including variable response, swallowing difficulty and combination-treatment burden.

Better delivery solves real patient friction.

Our Skill Set

Formulation science, regulatory strategy and commercial execution focused on high-value, poorly soluble medicines and scalable partner channels.

A mature platform built to repeat.

Growth Pillars

The strategic pillars that make EVE's platform commercial today.

Lead Asset in Market

Libbo is supplied under SAS-B, creating real-world prescription and patient-experience learnings.

Patient Differentiation

Improve established medicines through solubility, delivery format and a patient-centred experience.

Platform Repeatability

The nano-emulsion system applies across a broad range of poorly soluble drugs.

Commercial Infrastructure

Partnerships with patient-education, telehealth prescribing and pharmacy fulfilment providers are in place.

Accelerated Pathway

Bioequivalence-focused development supports a capital-efficient full product registration pathway.

Pipeline Depth

Men's Health, cardio-metabolic and future reformulation programs provide multiple opportunities.

Bioequivalence validation provides a capital-efficient proof point for full product registration.

The Erectile Dysfunction Market Opportunity

A large, growing market with high discontinuation and no established fast-onset oral alternative.

322m
Men globally affected by ED (2025)

USD 5.3B
Global ED drug market size (2025)

>50%
Patients who stop purchasing PDE5Is

Market Scale
The market is large; the patient experience remains under-served.

The Discontinuation Problem
Timing, planning and inconsistent response create friction.
EVE is focused on patients whom current formats do not serve well.

A meaningful patient need, a growing global market, and a clear delivery-format opportunity.

Current Treatment Failures

Why conventional treatments drive patient discontinuation.

Drug	Brand / format	Generic	Typical onset	Patient friction
Sildenafil	Viagra	Yes	1 hr+	Food effect / planning burden
Tadalafil	Cialis	Yes	1 hr+	Long duration, slower onset
Vardenafil	Levitra	Yes	45–60 min	Timing variability remains

30–35%
Patients report an inadequate or variable response

1 hr+
Typical onset time for conventional tablets

Up to 35%
Food effect reported for selected tablet formats

We're not fighting for share - we're picking up patients the incumbents are already losing. Libbo delivers the same active ingredient transmucosally, with onset in approximately 15 minutes.

** Onset is based on formulation design and an early 10-person observational study. Clinical validation is progressing via bioequivalence study.*

Libbo - The Solution

Vardenafil oral dissolving film: a reformulated medicine built around patient convenience.

What It Is

Vardenafil ODF: an established active ingredient in a fast-dissolving format.

How It Works

Nano-emulsion solubilisation supports transmucosal absorption.

Early Clinical Evidence

Early observational evidence informs the proposition; BE is the confirming next step.

Commercial Traction

LibX.com.au, telehealth and pharmacy partners form a live SAS-B pathway.

ORAL DISSOLVING FILM | TRANSMUCOSAL DELIVERY

LibX.com.au is EVE's patient education connection to prescribers.

ONSET COMPARISON

Standard tablets	Libbo
45–60 minutes	~15 minutes

Onset is based on formulation design and an early observational study. Further clinical validation is the confirming step.

One Platform. Many Compounds.

A repeatable nano-emulsion process for high-value poorly soluble drugs.



Insoluble Molecules

A proven compound with poor aqueous solubility limits conventional tablet performance.

Nano-emulsion Solubilisation

Proprietary process converts molecules into a stable nano-emulsion with improved effective solubility.

Oral Film or Oral Spray Delivery

Film and spray formats support fast, convenient transmucosal delivery.

Faster Onset, Improved Bioavailability

More consistent systemic exposure can improve patient outcomes.

- ✓ Enhanced Solubility
- ✓ Improved Bioavailability
- ✓ Fast-Onset Formats
- ✓ Patent-Pending
- ✓ Versatile
- ✓ Reduced Patient Variability

Proprietary nano-emulsion system - turn one proven product into a platform that keeps producing.
Libbo is proof of concept. The platform is the asset.

Validation Infrastructure Already Built

Ahead of full product registration, the end-to-end pathway is operating today.

Patient Education Platform
www.libx.com.au

›

Telehealth Consult
hubMed

›

SAS-B Prescription
Compliant clinical pathway

›

Pharmacy Fulfilment
Chemist2U

›

Home Delivery
Patient receives product with discreet delivery

- ✓ Patient acquisition model established
- ✓ Telehealth prescribing workflow proven
- ✓ Pharmacy logistics execution confirmed
- ✓ Regulatory compliance processes tested

PARTNER-LED GLOBAL ROLLOUT

Global partner conversations are underway across Asia, the Middle East, Europe and North America. Post-registration rollout is designed around established partner channels.

The operating pathway is in place - full commercial deployment can scale through established partner channels after registration.

The Patent Cliff

High-value medicines losing exclusivity create differentiated reformulation windows.

Target medicine	Global sales	Patent expiry	EVE relevance
Apixaban (Eliquis)	USD 12.2B	2026	Pre-BE development
Rivaroxaban (Xarelto)	USD 6.8B	2025	Screening
Xtandi (Enzalutamide)	USD 6.3B	2027	Screening
Farxiga (Dapagliflozin)	USD 6.0B	2025	Screening
Imbruvica (Ibrutinib)	USD 4.9B	2027	Screening

WHY THESE TARGETS? EVE screens medicines with established demand, approaching loss of exclusivity and a credible delivery-format advantage.

** Pending BE study. Market values are directional, based on referenced 2023/2024 global sales sources.*

Libbo is setting the path. The patent cliff creates a focused pipeline of established-medicine reformulation opportunities.

Accelerated Pathway

A capital-efficient route to product registration for established medicines.

Conventional new-drug development: Phase I → Phase II → Phase III → 10–15 years → hundreds of millions of dollars.

VS

Identify
High-value BCS Class II/IV candidate

›

Apply EVE's Technology
Nano-emulsion solubilisation

›

Product Validation
Real prescriber and patient feedback

›

BE Study
Confirming clinical-validation step

›

Registration
Scaled partner-led deployment

EVE's path focuses on bioequivalence for established molecules – faster, lower risk and more cost effective.

Multiple Pillars, One Platform

Libbo anchors the portfolio. One platform drives multiple franchises and future programs.

EVE's portfolio is structured around multiple complementary programs — all running off the same nano-emulsion platform.

MEN'S HEALTH FRANCHISE

Libbo (Vardenafil ODF)	*Erectile Dysfunction*	TGA SAS-B AVAILABLE
PE Program	*Premature Ejaculation*	IN DEVELOPMENT
ED/PE Combination	*Combined ED & PE*	IN DEVELOPMENT
BPH Program	*Combination Drug Film*	IN DEVELOPMENT

CARDIO-METABOLIC & FUTURE PROGRAMS

Apixaban Reformulation	*Anticoagulation*	PRE-BE DEVELOPMENT
Rosuvastatin Reformulation	*Lipid Lowering*	IN DEVELOPMENT
Atorvastatin Reformulation	*Lipid Lowering*	IN DEVELOPMENT

Screening Pipeline | Broader poorly soluble medicine universe under evaluation for future reformulation targets.

Key Milestones & Catalysts

Near-term value inflection points across the portfolio.

Timing	Milestone	Detail
Q1 2027	BE Study Commences	Libbo bioequivalence study initiated - confirming step toward full product registration.
H1 2027	PE Program Update	Pre-BE progress update on standalone premature ejaculation program.
H2 2027	Apixaban Pre-BE	Completion of pre-BE work on Apixaban reformulation program.
H2 2027	Registration Submission	Libbo product registration submission expected following BE study completion.

Timing reflects the current corporate planning view and is subject to clinical, regulatory and operational dependencies.

Why Invest in EVE

A product-led platform with multiple paths to value creation.

Product in Use

Libbo shows the platform can improve delivery of a known medicine.

IP Portfolio

Patents lodged to protect EVE's intellectual property.*

**Patents Pending*

Vast Market

ED, men's health and patent-cliff molecules create meaningful opportunity.

Scalable Model

Capital-light.
Channel-ready.
Partner led distribution.

SAS-B Revenue (today) → Licensing Milestones (near-term) → Scaled Partner-Led Revenue (post-registration)

Global partner conversations are underway across Asia, the Middle East, Europe and North America.

A lean R&D and regulatory focused model with immense scale and limitless potential. Potential is real, is here today, is proven, and is commercial.

Corporate Snapshot

Snapshot

ASX Ticker	EVE
Share Price (17 Sept 2026)	A$0.016
Shares on Issue	352m
Options on Issue	165m (4-6 cent exercise price)
Market Capitalisation (17 Sept 2026)	A$5.6m
Cash (30 June 2026)	A$1.2m
Enterprise Value	A$4.4m
Debt (17 Sept 2026)	Nil

Board	Role
Rodney Hannington	Non-Executive Chairman
Dr Stuart Gunzburg	Executive Director & Chief Scientific Officer
Bill Fry	Non-Executive Director

Management	Role
Ben Rohr	Chief Executive Officer
Steven Jackson	Chief Financial Officer & Company Secretary

Ownership



Board & Management

Experienced leadership across pharmaceutical science, commercial execution and governance.

BOARD OF DIRECTORS

Dr Stuart Gunzburg

CHIEF SCIENTIFIC OFFICER & EXECUTIVE DIRECTOR

Medical researcher and entrepreneur whose pioneering nano-emulsion work underpins EVE's pharmaceutical formulations.

Rodney Hannington

NON-EXECUTIVE DIRECTOR

Former Novartis Consumer Health leader with strategy and innovation experience across Asia, the Middle East and Africa.

Bill Fry

NON-EXECUTIVE DIRECTOR

Corporate leader and investor with two decades across life sciences, ctal markets, M&A and project development.

EXECUTIVE MANAGEMENT

Ben Rohr

CHIEF EXECUTIVE OFFICER

20+ years across pharmaceuticals, wellness, finance and consumer sectors. Leads EVE's licensing-focused commercial strategy.

Steven Jackson

CHIEF FINANCIAL OFFICER

Qualified accountant with extensive corporate finance and public-company financial management experience.

Elizabeth Gibbon

PROJECTS MANAGER

Experienced project manager coordinating development activities and regulatory submissions.

Important Notice & Disclaimer

This presentation (Presentation) has been prepared by EVE Health Group Limited ABN 89 106 523 611 (EVE or the Company). The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. The information in this presentation is subject to change without notice and, subject only to any legal obligations to do so, EVE does not have any obligation to correct or update the contents of this Presentation.

The Presentation contains certain "forward-looking statements". The words "forecast", "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice and involve known and unknown risks and certainties and other factors which are beyond the control of EVE, and its directors and management, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. This includes statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. Recipients are cautioned not to place undue reliance on forward-looking statements. Refer to the risk factors section of this Presentation for some of the key known risks. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation. The forward-looking statements are based on information available to EVE as at the date of this Presentation. Circumstances may change and the contents of this Presentation may become outdated as a result. Except as required by law or regulation, none of EVE, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

No party other than EVE has authorised or caused the issue, lodgement, submission, dispatch or provision at the end of this Presentation, or takes any responsibility for, or makes or purports to make any statements, representations or undertakings in this Presentation. To the maximum extent permitted by law, EVE (including its subsidiaries, related bodies corporate, shareholders, affiliates, advisers and agents):

- disclaims all responsibility and liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss arising from this Presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentation;
- disclaims any obligations or undertakings to release any updates or revision to the information in this Presentation to reflect any change in expectations or assumptions; and
- does not make any representation or warranty, express or implied, as to the accuracy, reliability or completeness of the information in this Presentation or the likelihood of fulfilment of any forward-looking statement or any event or results expressed or implied in any forward-looking statement.

Not an offer
This Presentation is not a prospectus, product disclosure document or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation is for information purposes only and should not be considered as, an offer, solicitation, inducement, recommendation or an invitation to acquire securities in EVE or any other financial products, and neither this document nor any of its contents will form the basis of any contract or commitment. This Presentation may not be distributed to any person in any country outside Australia except to the extent permitted under applicable laws. The release, publication or distribution of this Presentation (including an electronic copy) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and should seek your own advice on such restrictions. Any non-compliance with these restrictions may contravene applicable securities laws.

Not financial product advice
This Presentation is not financial product, investment advice or a recommendation to acquire EVE securities and has been prepared without taking into account the objectives, financial situation or needs of individuals. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation including, but not limited to, the assumptions, uncertainty and contingencies which may affect future operations of EVE and the impact that different future outcomes may have on EVE. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. EVE is not licensed to provide financial product advice in respect of its securities or any other financial products.

Clinical and regulatory information
Clinical data referenced in this Presentation in relation to Libbo and Dyspro is based on formulation design targets and the results of an early, small-scale observational study involving approximately 10 participants. This data has not been generated or reviewed under the conditions of a registered clinical trial and should not be interpreted as demonstrating clinical equivalence, efficacy, safety or bioavailability comparable to any registered reference product. Formal clinical validation, including a bioequivalence study, is in progress but has not been completed as at the date of this Presentation. Onset of action, bioavailability, and any other performance claims referenced or implied in this Presentation remain subject to confirmation through that clinical validation process and may differ materially from the observational data referenced. No representation or warranty is given that the results of the bioequivalence study, once completed, will support the formulation design targets or observational data referred to in this Presentation.

Libbo and Dyspro are prescription medicines. Products supplied under the Therapeutic Goods Administration's Special Access Scheme B (SAS-B) pathway are unapproved therapeutic goods and are not listed, registered or otherwise included on the Australian Register of Therapeutic Goods (ARTG). The TGA has not evaluated these products for quality, safety or efficacy for the purposes of ARTG listing or registration. Supply under SAS-B is at the discretion of, and remains the responsibility of, the treating medical practitioner, who has determined that use of the product is appropriate for a specific patient on a case-by-case basis under the applicable regulatory framework. There is no assurance that Libbo, Dyspro or any other product referenced in this Presentation will achieve full TGA registration or ARTG listing, or that any such approval will be obtained within the timeframe, or on the terms, anticipated by the Company.

Authorisation for release
This presentation has been authorised for release by the Chief Executive Officer, Mr Ben Rohr.

References

Sources supporting the market, clinical and regulatory claims in this presentation.

Previous Disclosure

• “EVE to Acquire Nextract, Expanding into $5.3B Erectile Dysfunction Market”, 14 April 2025. Acquisition rationale; ED market; oral soluble-film platform; targeted ~15-minute onset; SAS-B / Authorised Prescriber pathway.

• “EVE and TeleDocs Clinic Sign National Prescribing Agreement for Erectile Dysfunction Oral Soluble Film and Dysmenorrhea Gummy”, 16 June 2025. National telehealth prescribing and pharmacy-support pathway.

• “Regulatory Milestones met”, 21 July 2025. Regulatory pathway, product stability and planned commercial access.

• “EVE Signs Telehealth Services Agreement with hubMed”, 19 November 2025. Additional national telehealth and patient-support infrastructure.

• “Libbo Production Complete”, 30 January 2026; “Libbo Launch”, 10 February 2026. Commercial manufacture, launch and end-to-end patient access and fulfilment pathway.

• “EVE Advances Reformulated Drugs Targeting Global Markets”, 10 March 2026. Reformulation strategy, patent-cliff rationale, expanded sexual-health and cardiovascular pipeline and Apixaban program.

• “EVE Initiates Pilot Clinical Study for Libbo ED Film”, 16 June 2026. Vardenafil 10 mg oral soluble film; pilot PK study; reference-tablet comparison; planned pivotal bioequivalence pathway.

External / Scientific Sources

• Special Access Scheme, Category B guidance - www.tga.gov.au/business-services/special-access-scheme-and-authorised-prescriber-online-system/access-unapproved-therapeutic-goods-individual-patients-special-access-scheme

• The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences - pubmed.ncbi.nlm.nih.gov/10444124/

• First-generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and meta-analysis - pubmed.ncbi.nlm.nih.gov/27636710/

• Treating erectile dysfunction when PDE5 inhibitors fail - pubmed.ncbi.nlm.nih.gov/16528082/

• The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue - pubmed.ncbi.nlm.nih.gov/31350821/

• A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability - pubmed.ncbi.nlm.nih.gov/7617530/

• Erectile Dysfunction Drugs Market - https://www.coherentmarketinsights.com/market-insight/erectile-dysfunction-market-200

1/245 Churchill Ave, Subiaco WA 6008
+61 8 6465 5500
info@evehealthgroup.com.au

WWW.EVEHEALTHGROUP.COM.AU